InflaRx Announces Peer-Reviewed Publication Of First-In-Human Phase 1 Clinical Data For Izicopan, Orally Administered, Next-Gen Small Molecule Inhibitor Of C5a Receptor

• Izicopan achieved rapid and sustained inhibition of C5a/C5aR1 signaling
• Pharmacokinetic results demonstrated dose-dependent exposure, with izicopan well tolerated across all single and multiple doses evaluated
• Findings support Phase 2 development of izicopan in immune-inflammatory diseases
   

Jena, Germany, Nov. 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the peer-reviewed publication of first-in-human Phase 1 clinical data for izicopan, formerly known as INF904, the Company’s orally administered, next-generation small molecule inhibitor of the C5a receptor (C5aR1). The publication reports results from the Company’s single ascending dose (SAD) and multiple ascending dose (MAD) study in 86 healthy participants. The positive results of these studies were previously announced.

The paper, "A First-In-Human, Randomized, Placebo-Controlled Single and Multiple Ascending Dose Study of Izicopan (INF904), A Second-Generation Oral Small Molecule C5a Receptor Inhibitor, in Healthy Participants," was published in the peer-reviewed journal, Clinical Pharmacology in Drug Development. The publication reports findings from a randomized, placebo-controlled Phase 1 study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of izicopan in 86 healthy volunteers.